Grimes & Company Inc. reduced its position in shares of Novartis AG (NYSE:NVS) by 3.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,647 shares of the company’s stock after selling 1,099 shares during the period. Grimes & Company Inc.’s holdings in Novartis AG were worth $2,717,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of NVS. Massachusetts Financial Services Co. MA boosted its holdings in shares of Novartis AG by 0.5% during the first quarter. Massachusetts Financial Services Co. MA now owns 279,163 shares of the company’s stock worth $20,734,000 after purchasing an additional 1,314 shares during the period. Loomis Sayles & Co. L P boosted its holdings in shares of Novartis AG by 0.7% during the first quarter. Loomis Sayles & Co. L P now owns 6,241,239 shares of the company’s stock worth $463,537,000 after purchasing an additional 41,762 shares during the period. Primecap Management Co. CA boosted its holdings in shares of Novartis AG by 2.1% during the first quarter. Primecap Management Co. CA now owns 21,693,804 shares of the company’s stock worth $1,611,199,000 after purchasing an additional 446,976 shares during the period. MARSHALL WACE ASIA Ltd purchased a new stake in shares of Novartis AG during the first quarter worth about $51,367,000. Finally, Marshall Wace North America L.P. purchased a new stake in shares of Novartis AG during the first quarter worth about $51,367,000. Institutional investors own 10.94% of the company’s stock.

A number of research firms have recently weighed in on NVS. BidaskClub lowered shares of Novartis AG from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Cowen and Company set a $90.00 target price on shares of Novartis AG and gave the stock a “hold” rating in a report on Wednesday, August 9th. J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis AG in a report on Tuesday, October 31st. Leerink Swann lifted their target price on shares of Novartis AG from $89.00 to $91.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Finally, Barclays PLC downgraded shares of Novartis AG from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, October 25th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $85.28.

Novartis AG (NVS) traded down $0.35 on Friday, hitting $82.13. 495,543 shares of the company were exchanged, compared to its average volume of 2,090,000. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08. Novartis AG has a 52 week low of $66.93 and a 52 week high of $86.90. The stock has a market cap of $212,980.00, a PE ratio of 17.46, a price-to-earnings-growth ratio of 2.65 and a beta of 0.72.

Novartis AG (NYSE:NVS) last released its earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.04. Novartis AG had a net margin of 13.73% and a return on equity of 15.77%. The company had revenue of $12.41 billion for the quarter, compared to analysts’ expectations of $12.21 billion. During the same quarter in the previous year, the company earned $1.23 EPS. Novartis AG’s revenue for the quarter was up 2.4% on a year-over-year basis. equities research analysts anticipate that Novartis AG will post 4.75 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/grimes-company-inc-has-2-72-million-stake-in-novartis-ag-nvs/1693718.html.

Novartis AG Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.